The global biopharma industry and the rise of Indian drug multinationals: implications for Australian generics policy
2007
The Rise of Indian Drug Companies and Its Impact on Australian Generics Policy
publication
Author Information
Author(s): Hans Löfgren
Primary Institution: Deakin University
Conclusion
The rise of Indian biopharma multinationals is reshaping the generics market in Australia, leading to lower prices but challenging local manufacturing.
Supporting Evidence
- Indian biopharma companies are now major suppliers of Active Pharmaceutical Ingredients and generic drugs.
- The generics segment in Australia is expected to see high growth rates in the coming years.
- Lower generics prices will negatively impact some local suppliers.
Takeaway
Indian drug companies are becoming really good at making medicines, which means they can sell them for less money. This is good for people who need the medicines but makes it hard for local companies in Australia to compete.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website